IP Library › Granted Patent US 8,080,423
Granted Patent B2
US 8,080,423 · App. 11/573,179 · Granted Dec 20, 2011

Reagent containing protease reaction promoter and/or colorant stabilizer

Assignee: Asahi Kasei Pharma Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,080,423
App. No.
11/573,179
Granted
Dec 20, 2011
Kind
B2
Abstract

Stabilizers for colorants used for detection of enzymatic reactions, having a cyclodextrin and a catalase; reagents including stabilizers; and methods of use of such stabilizers and reagents.

Claims (15)

1. A method for stabilizing a kit of compositions comprising a first composition and a second composition used for the measurement of glycated hemoglobin or glycated albumin in a sample comprising:

making a protease, 10-(carboxymethylaminocarbonyl)-3,7-bis(dimethylamino)phenothiazine, and a cyclodextrin coexist together in the absence of a sample containing glycated hemoglobin or glycated albumin, and thereby providing the first composition comprising the protease, 10-(carboxymethylaminocarbonyl)-3,7-bis(dimethylamino)phenothiazine, and the cyclodextrin with no sample containing glycated hemoglobin or glycated albumin, and

providing the second composition containing an oxidase which oxidizes a glycated amino acid and/or a glycated peptide,

wherein the first and second compositions of the kit remain stable in a liquid state for 6 months or longer under refrigeration in the absence of a sample containing glycated hemoglobin or glycated albumin.

2. The method according to claim 1 , wherein the cyclodextrin is a β-cyclodextrin.

3. The method according to claim 1 , wherein the first composition containing the protease, 10-(carboxymethylaminocarbonyl)-3,7-bis(dimethylamino)phenothiazine, and the cyclodextrin further comprises a buffer in a concentration of 100 mM or less.

4. The method according to claim 3 , wherein the first composition containing the protease, 10-(carboxymethylaminocarbonyl)-3,7-bis(dimethylamino)phenothiazine, and the cyclodextrin further comprises a buffer in a concentration of 80 mM or less.

5. A method of measuring glycated hemoglobin or glycated albumin in a blood sample, comprising:

adding to the blood sample,

the first composition stabilized by the method according to claim 1 , thus providing a mixture of the blood sample and the first composition,

adding to the mixture the second composition according to claim 1 , and

detecting through the activity of the oxidase which oxidizes a glycated amino acid and/or a glycated peptide, the presence of glycated amino acids and/or glycated peptides cleaved from glycated hemoglobin or glycated albumin present in the blood sample.

6. The method according to claim 5 , wherein the cyclodextrin is a β-cyclodextrin.

7. The method according to claim 5 , wherein the first composition containing the protease, 10-(carboxymethylaminocarbonyl)-3,7-bis(dimethylamino)phenothiazine, and the cyclodextrin further comprises a buffer in a concentration of 100 mM or less.

8. The method according to claim 7 , wherein the first composition containing the protease, 10-(carboxymethylaminocarbonyl)-3,7-bis(dimethylamino)phenothiazine, and the cyclodextrin further comprises a buffer in a concentration of 80 mM or less.

Assignments (4)
NUNC PRO TUNC ASSIGNMENT Recorded Dec 1, 2025
From: ASAHI KASEI PHARMA CORPORATION
To: NAGASE DIAGNOSTICS CO., LTD.
Reel/Frame 073061/0129 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 027096 FRAME 0398. ASSIGNOR(S) HEREBY CONFIRMS THE ADDRESS OF THE ASSIGNEE IS 1-105, KANDA JINBO-CHO, CHIYODA-KU, TOKYO, JAPAN. Recorded Nov 28, 2011
From: ASAHI KASEI PHARMA CORPORATION
To: ASAHI KASEI PHARMA CORPORATION
Reel/Frame 027282/0911 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE THIRD INVENTOR PREVIOUSLY RECORDED ON REEL 019049 FRAME 0273. ASSIGNOR(S) HEREBY CONFIRMS THE NAME OF THE THIRD INVENTOR IS SHIGEYUKI IMAMURA. Recorded Oct 20, 2011
From: KOUZUMA, TAKUJI; NAGAI, YOKO; IMAMURA, SHIGEYUKI
To: ASAHI KASEI PHARMA CORPORATION
Reel/Frame 027096/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2007
From: KOUZUMA, TAKUJI; NAGAI, YOKO; NAGAI, SHIGEYUKI
To: ASAHI KASEI PHARMA CORPORATION
Reel/Frame 019049/0273 →
Priority Claims (2)
JP 2004-229498 · Aug 5, 2004 · national
JP 2004-281226 · Sep 28, 2004 · national
Continuity (1)
Related Publication 20070224685A1 · Sep 27, 2007